Drug Profile


Alternative Names: Airitis; L-cetirizine; Levocetirizine dihydrochloride; Xazal; Xevor; Xozal; Xusal; Xuzal; Xysal; Xyzal; Xyzall

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Sepracor
  • Developer GlaxoSmithKline; UCB
  • Class Antiallergics; Nonsedating antihistamines; Piperazines; Small molecules
  • Mechanism of Action Histamine H1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Allergic rhinitis; Dermatitis; Perennial allergic rhinitis; Pruritus; Seasonal allergic rhinitis; Urticaria
  • Discontinued Asthma

Most Recent Events

  • 17 Apr 2016 Biomarkers information updated
  • 30 Apr 2012 Phase-III clinical trials in Allergic rhinitis (in children) in Japan (PO)
  • 30 Apr 2012 Phase-III clinical trials in Pruritus (in children) in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top